SF3B1 and Thrombocytosis: Further studies are also required to assess the impact of this drug on other myeloid neoplasms associated with anemia such as myelodysplastic syndromes with ring sideroblasts or SF3B1 mutation, especially those with co-expression of a JAK2 mutation and thrombocytosis.